Abstract
Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Current Drug Targets - Inflammation & Allergy
Title: Macrophages in Inflammatory Bowel Disease
Volume: 2 Issue: 2
Author(s): Olof Grip, Sabina Janciauskiene and Stefan Lindgren
Affiliation:
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Abstract: Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Export Options
About this article
Cite this article as:
Grip Olof, Janciauskiene Sabina and Lindgren Stefan, Macrophages in Inflammatory Bowel Disease, Current Drug Targets - Inflammation & Allergy 2003; 2 (2) . https://dx.doi.org/10.2174/1568010033484179
DOI https://dx.doi.org/10.2174/1568010033484179 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Differential Expression of miR-31 between Inflammatory Bowel Disease and Microscopic Colitis
MicroRNA Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Current Concepts on the Genetics and Pharmacogenetics of Inflammatory Bowel Disease: Do they Help in Clinical Management?
Current Genomics Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Mucosal Healing in Ulcerative Colitis: Where do we Stand?
Current Drug Targets New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Potassium Channel Openers and Improvement of Toxic Stress: Do they have Role in the Management of Inflammatory Bowel Disease?
Inflammation & Allergy - Drug Targets (Discontinued) Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Guar Gum and HPMC Coated Colon Targeted Delivery of 6-Mercapto-Purine
The Natural Products Journal Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials Colon as Target for Drug Delivery
Current Drug Therapy Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design